You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Navigo and Mannin agree to develop a novel drug for treating COVID-19

Navigo and Mannin have entered into an agreement to develop a ‘precision X’ affinity ligand against the fusion protein of angiopoietin-1 and complement 4 binding protein (Ang1-C4bp) for use in manufacturing.